KOD

Kodiak Sciences Inc.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc. (KOD) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
D-
Factor Score 0.7 / 5.0
Momentum
A+
Factor Score 5.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -31.5
EV / EBITDA -29.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 161.8%
Price Return 12M 451.4%
Catalyst Signal 0.00
Market Cap $6.8B
TTM Revenue N/A
Price / Sales N/A
ROE -368.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C- (2.1) D- (0.7) A+ (5.0) C+ (2.6) C+ (2.6)
2026-11-06 C+ (2.5) C- (2.0) D- (0.7) A+ (4.5) C+ (2.7) C (2.5)
2026-10-30 C+ (2.5) C- (2.0) D- (0.8) A+ (4.9) C+ (2.7) C+ (2.6)
2026-10-23 C+ (2.5) C- (2.0) F (0.7) B (3.2) C+ (2.6) C (2.2)
2026-10-16 C+ (2.5) C- (2.0) F (0.7) C (2.4) C+ (2.6) C- (2.0)
Page 1 of 3